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Abstract
Pediatric high-grade gliomas (pHGGs), with a two-year survival rate of less than 20%, are some of the
most aggressive human cancers. This dissertation begins with our analysis of 127 pHGGs, including
brainstem (BS) and non-brainstem (NBS) tumors, from 118 patients using next-generation sequencing
technologies. Nearly one-third of BS-HGGs, also known as diffuse intrinsic pontine gliomas (DIPGs),
harbored somatic heterozygous missense mutations in ACVR1, coding for a receptor serine-threonine
kinase involved in bone morphogenetic protein (BMP) signaling. These alterations led to gain-of-function
as evidenced by increased phosphorylation of downstream targets in primary astrocytes and zebrafish
embryo ventralization. Whole-genome sequencing and RNASeq revealed that nearly half of our cohort
contained structural variants. We identified recurrent gene fusions preserving the kinase domain of the
neurotrophin family of receptor tyrosine kinases (NTRK) including three novel fusions and two fusions
previously described in other tumor types. NTRK fusion genes were identified in 40% of infant (<3 years
of>age) NBS-HGGs, and 7% of pHGG overall. We also found that infants have significantly reduced
mutation burdens when compared to pHGGs in older children, suggesting a small number of oncogenic
mutations are required in infant tumors. These findings, coupled with the observation that infants have a
better prognosis than non-infants, make infant NBS tumors a distinct subgroup of pHGG. NTRK gene
fusions also occur in pediatric low-grade glioma (pLGG) and adult glioblastoma but are not as enriched as
they are in infant NBS-HGG, and adult glioblastoma and non-infant pHGGs exhibit higher mutation rates
than infant tumors. NTRK fusion genes are therefore gliomagenic drivers throughout various development
settings; yet it appears as if gliomas driven by the same oncogenic lesion can vary in tumor phenotype as
a function of contextual differences. With this in mind, we used genetically engineered mice with a NTRK
gene fusion knock-in allele to generate HGG in vivo. Given that tumor is evident by early postnatal life (P5),
this is, to our knowledge, the first report of a bona fide spontaneous pHGG model. The second part of this
dissertation is the characterization of these tumors.
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ABSTRACT
Pediatric high-grade gliomas (pHGGs), with a two-year survival rate of less than
20%, are some of the most aggressive human cancers. This dissertation begins with our
analysis of 127 pHGGs, including brainstem (BS) and non-brainstem (NBS) tumors,
from 118 patients using next-generation sequencing technologies. Nearly one-third of
BS-HGGs, also known as diffuse intrinsic pontine gliomas (DIPGs), harbored somatic
heterozygous missense mutations in ACVR1, coding for a receptor serine-threonine
kinase involved in bone morphogenetic protein (BMP) signaling. These alterations led to
gain-of-function as evidenced by increased phosphorylation of downstream targets in
primary astrocytes and zebrafish embryo ventralization. Whole-genome sequencing and
RNASeq revealed that nearly half of our cohort contained structural variants. We
identified recurrent gene fusions preserving the kinase domain of the neurotrophin family
of receptor tyrosine kinases (NTRK) including three novel fusions and two fusions
previously described in other tumor types. NTRK fusion genes were identified in 40% of
infant (<3 years of age) NBS-HGGs, and 7% of pHGG overall. We also found that
infants have significantly reduced mutation burdens when compared to pHGGs in older
children, suggesting a small number of oncogenic mutations are required in infant
tumors. These findings, coupled with the observation that infants have a better prognosis
than non-infants, make infant NBS tumors a distinct subgroup of pHGG. NTRK gene
fusions also occur in pediatric low-grade glioma (pLGG) and adult glioblastoma but are
not as enriched as they are in infant NBS-HGG, and adult glioblastoma and non-infant
pHGGs exhibit higher mutation rates than infant tumors. NTRK fusion genes are
therefore gliomagenic drivers throughout various development settings; yet it appears as
if gliomas driven by the same oncogenic lesion can vary in tumor phenotype as a function
of contextual differences. With this in mind, we used genetically engineered mice with a
NTRK gene fusion knock-in allele to generate HGG in vivo. Given that tumor is evident
by early postnatal life (P5), this is, to our knowledge, the first report of a bona fide
spontaneous pHGG model. The second part of this dissertation is the characterization of
these tumors.
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CHAPTER 1.

INTRODUCTION*

Introductory Comments
Cancer is unequivocally a genetic disease. That fact is so fundamental to our
understanding that we oftentimes take it for granted. Indeed, it is difficult for us to even
fathom a paradigm that predates our own. However, the history of cancer, or rather its
written history, stretches as far back as 3000 BC with Ancient Egyptian descriptions of
breast tumors. And since then, theories of cancer etiology have been just as varied as the
cancer themselves; from explanations such as gods and humoral imbalance to more
recent hypotheses including lymph and blastema theory[1]. The isolation of DNA in
1869[2] did not immediately seem relevant to the study of cancer, and it would take until
the mid-20th century for the inception of oncogene theory[3]. Since that time, cancer
biology has become predicated upon genetic alterations leading to gain-and-loss-offunction of proteins involved in every cellular function imaginable, from signaling
cascades promoting cell survival and proliferation to DNA damage repair to epigenetic
regulation. The combination of events leading to neoplasia are varied, perhaps
innumerable. Yet regardless of its complexity, cancer is a disease of a singular process:
perturbation conferring a selective advantage.
The role of genetic alterations in cancer, both inherited and acquired, is an
obvious one. What has become evident more recently is the idea that cancers arising in
adults are different from those in children. There are common cases for adult oncologists,
such as lung cancer, that are rare for pediatric physicians and vice versa[4]. True as that
may be, for cancers that occur throughout life the histopathology is indistinguishable
between adults and children. This in turn led to the thinking that similar histology was the
result of similar underlying genetics; resulting in the thinking that children are “little
adults.” Fast forward to the 21st century. We can comfortably assert, informed by decades
of genetic and molecular analyses, that such thinking is decidedly wrong. That is not to
say there is no overlap whatsoever. Adult and pediatric cancers are indeed related, but
they are also distinct. One issue that remains unresolved is the idea that pediatric cancers
arise from an underlying genetic susceptibility. Many believe that the only way children
can acquire the necessary hits for tumor formation, given their reduced latency, is
through germline mutations leading to cancer predisposition syndromes. After
sequencing thousands of tumor/matched normal pairs, we are still uncertain whether this
is indeed the case or not. Only a minority of children who develop cancer carry germline
mutations in known susceptibility genes[5]. However, our understanding of protein
coding sequences is far from comprehensive and that of the remaining 98% of the noncoding genome is even less; so the functional consequence of the ever-expanding catalog
of germline variants identified in pediatric cancer patients remains to be seen[6]. What
____________________________
*
Reprinted with permission. Diaz, A.K. and S.J. Baker, The genetic signatures of
pediatric high-grade glioma: no longer a one-act play. Semin Radiat Oncol, 2014. 24(4):
p. 240-7.
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this data has also revealed is that generally speaking, pediatric cancers exhibit lower
mutation burdens than cancers more commonly seen in adults. Interestingly, but not
altogether surprising, malignancies with known associations with environmental
mutagens, such as lung and colorectal cancers, have some of the highest mutation
burdens evident[7]. But it is important to keep in mind that there also exists heterogeneity
within a given tumor type. For example, pediatric high-grade gliomas, an aggressive
brain tumor that will be the focus of this dissertation, range from some of the quietest
cancer genomes to having a hypermutator phenotype[8-11].
The Genomic Era continues onward, but it has already yielded critical insight.
The differences between pediatric and adult cancers highlight the central importance
developmental context plays in pathogenesis. But rather than merely serving as a
backdrop, developmental context is an active participant, from determining the cell
populations involved to influencing what genes are expressed. Yes, there are common
pathways dysregulated in various cancer types regardless of age. And this should come as
no surprise given their roles in cellular processes such as cell survival and proliferation.
Yet when we look a bit more closely, we begin to see differences emerge as targeted
effectors tend to differ between adults and children. Moreover, in certain instances we see
involvement of a particular pathway/mechanism in one age group that does not appear
implicated in the other.
The success of the Genomic Era goes without saying. We now have a much better
idea of who the culprits are (genetic events) in tumor formation. Exactly how these
alterations are contributing to cancer is now the imperative; because it is with this
knowledge that we can then attempt to take advantage of them therapeutically.
High-Grade Gliomas
Experts predict that nearly 80,000 new cases of primary brain/central nervous
system (CNS) tumors will be diagnosed in the United States in 2016; primary meaning
disease originating in the brain/CNS compared to metastases. Those estimates also
indicate that about one-third of these cases will be malignant[12]. Brain tumors present
clinicians with unique challenges that differ from other cancers. For one, most deaths
from brain tumors are the consequence of a growing mass encased within a confined
space leading to increased intracranial pressure resulting in loss of brain function[13, 14].
Additionally, the blood-brain barrier, which works in keeping harmful substances outside
of the CNS, works in keeping potentially efficacious chemotherapies out as well[15]. As
a result, certain brain tumors remain some of the most lethal cancers.
Pathologists formally diagnose these cases by how they appear through the
microscope; specifically, by cell morphology and protein expression via
immunohistochemistry (IHC). If a tumor exhibits features of astrocytes,
oligodendrocytes, or both, then it is referred to as a glioma. The most commonly used
scheme for grading gliomas is that developed by the World Health Organization (WHO).
It is a I-IV scale with grade I denoting the most benign form of disease and grade IV (also
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known as glioblastoma) being the most aggressive. Going from grade I to grade IV,
tumors exhibit increased mitotic activity, nuclear atypia, and anaplasia. Gliomas graded
III and IV are collectively known as high-grade gliomas (HGG) whereas grades I and II
are regarded as low-grade gliomas (LGGs)[16].
Given the morphology that defines gliomas, it is logical to assert that they arise
from glial cells. But specifically which one/s? In short, the issue remains unresolved.
Gliogenesis is a highly complex process that involves a number of different cell types
including stem and progenitor cells as well as transit-amplifying populations and of
course fully differentiated astrocytes and oligodendrocytes. And when we take a look at
the experimental data, a number of these possess the capacity to transform, leading to
glioma formation. Glia formation in utero follows neurogenesis and continues throughout
post-natal development. Multipotent neural stem cells (NSCs) divide asymmetrically
yielding neuronal progenitors, astrocytic progenitors, and oligodendrocyte precursor cells
(OPCs), with each giving rise to its differentiated namesake progeny. NSC populations
persist even into adulthood, populating the subventricular zone (SVZ) and dentate gyrus,
specifically the subgranular zone[17]. Evidence supporting NSCs as a putative cell-oforigin includes the ability of proliferative niches to generate gliomas in mice upon
retroviral delivery of oncogenic mutations; whereas those same alterations failed to
induce gliomagenesis outside of these niches[18-20]. Moreover, targeted depletion of
cells expressing nestin (an intermediate filament and NSC marker) significantly impaired
tumor growth in vivo[21]. As for the role of astrocytes in tumor initiation, numerous
studies have been conducted taking genetically altered primary astrocyte cultures and
implanting them into recipient mice with subsequent glioma formation[8, 22-29].
Spontaneous models have also implicated astrocytes; using an inducible expression
system, researchers targeted Cre-mediated recombination in adult brains, specifically in
cells expressing glial fibrillary acidic protein (GFAP). And although the marker is
expressed both in astrocytes and NSCs, nearly a quarter of the gliomas that formed did so
outside of the SVZ and subgranular zone, with no evidence of disease originating in those
areas. Albeit indirectly, what this demonstrates is an increased capacity of NSCs to
transform relative to astrocytes but with astrocytes still possessing such potential[30].
Aside from the growing experimental literature supporting OPCs as glioma initiating
cells[31], a particular gene expression signature associated with HGG, known as the
proneural subtype, shows extensive overlap with OPCs[32]. This, coupled with the fact
that OPCs actually outnumber NSCs in the adult brain[33-35], leads many to believe that
at least a portion of HGGs arise from this cell population.
Even prior to interrogation with microarrays or next-generation sequencing
(NGS), it was reasonable to suspect that pediatric gliomas were different from those in
adults. For one, the majority of adult gliomas are high-grade whereas in children, the
most common gliomas are low-grade tumors. Also, where gliomas arise differs as a
function of age: most gliomas in adults occur in the cerebral hemispheres while in
children, a broader range of areas are affected. High-grade tumors of the brainstem are
commonly referred to as diffuse intrinsic pontine gliomas (DIPGs). Brainstem HGGs
almost exclusively occur in children, making it a uniquely pediatric disease, and roughly
half of pediatric HGG cases are DIPGs[12, 36]. Another distinguishing feature between
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adult and pediatric gliomas is the frequency of malignant transformation, the process
where a patient presents with a high-grade tumor that was previously diagnosed as a
lower grade[37]. Lastly, the current standard of chemotherapeutic care for adult highgrade glioma, the alkylating agent temozolomide, has not been shown to improve
survival in pediatric trials[38-40]. Collectively, these observations hinted at the
possibility of pediatric HGG (pHGG) having a distinct genetic etiology from adult HGG
(aHGG).
The Genetics of Adult and Pediatric High-Grade Glioma
A great deal of work has gone into uncovering the genetics underlying HGG.
During my time as a graduate student, I published a review that was intended to be a
comparative analysis between the adult and pediatric forms of the disease. Quoted text in
this section is taken from that review[41].
Genetic studies of aHGG, specifically glioblastoma, revealed dysregulation in
three main networks: the retinoblastoma (RB), p53, and receptor tyrosine kinase (RTK)Ras-phosphotidylinositide 3-kinase (PI3K) pathways[42-44]. “The p53 and RB pathways
regulate G1 cell cycle checkpoints. Mitogenic signaling activates the cyclin D-dependent
kinases CKD4 or CKD6, coupled with cyclin D family members (CCND1/2/3). This
complex phosphorylates pRB, releasing E2F and promoting transcription of genes
responsible for G1-S cell cycle progression. The tumor suppressor locus CDKN2A
encodes 2 different proteins through translation of 2 different reading frames, p16INK4A
and p19ARF. p16INK4A inhibits the activity of the cyclin D-dependent kinases CKD4
and CKD6. Oncogenic signals, DNA damage, or induction of p19ARF induces p53,
leading to cell cycle arrest, apoptosis, or senescence[45]. Mutations in the RTK-RasPI3K pathway transduce unregulated signals for cell proliferation, growth, and survival.
RTK signaling begins when growth factor ligand binding leads to receptor dimerization.
Upon dimerization, RTKs trans-phosphorylate one another at tyrosine residues in their
cytosolic tails. p85, the regulatory subunit of PI3K, can then either directly bind to these
phosphorylated tyrosine residues or connect to RTKs through adaptor molecules and Ras.
PI3K comprises catalytic (p110) and regulatory (p85) subunits (Figure 1-1)[46].
As the genomic landscape of aHGG came into view, it shaped initial work into
the pediatric disease. The first pHGG studies focused primarily on investigating the
involvement of high-frequency recurrent events found in adult tumors. For example,
epidermal growth factor receptor (EGFR) is the most commonly altered RTK in aHGG;
with the corresponding gene locus undergoing amplification or intragenic deletion or
both in ~50% of cases[42-44]. First identified in adult glioblastoma, EGFR variant III
(EGFRvIII) is the most common EGFR variant in aHGG and is formed by deletion of
exons 2-7 resulting in a constitutively active kinase[47-49]. Accordingly, investigators
early on sought to examine the degree of EGFR involvement in pediatric cases of HGG.
A number of studies found that EGFR alteration was less frequent in pHGG[5056], although gene amplification and EGFRvIII expression were detected in some
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Figure 1-1. The p53, RB, and RTK-Ras-PI3K pathways are dysregulated in both
adult and pediatric HGG.
(A) The p53 and RB pathways regulate G1 cell cycle checkpoints. Mitogenic signaling
leads to activation of the cyclin D-dependent kinases, CKD4 or CKD6, coupled with
cyclin D family members, which confer substrate specificity. CDK4/6-Cyclin D
complexes, in turn, phosphorylate pRB, facilitating E2F-mediated transcription of genes
leading to G1-S cell cycle progression. Gene amplifications of CDK4, CDK6, or the 3
cyclin D family members (CCND1/2/3) are found in pHGG, and moreso in DIPG. The
tumor suppressor locus CDKN2A encodes 2 different proteins, p16INK4A and p19ARF.
p16INK4A inhibits CDK4/6-Cyclin D complex activity. Oncogenic signals, DNA
damage, or induction of p19ARF upregulates p53 expression, leading to cell cycle arrest,
apoptosis, or senescence. Homozygous deletions of CDKN2A occur almost exclusively in
pediatric NBS-HGGs, whereas TP53 mutations are common regardless of age or
location. (B) RTK signaling initiates when growth factors bind, leading to
receptor dimerization. In pHGG, PDGFRα is the most commonly targeted RTK, either by
amplification or mutation or both. Upon dimerization, RTKs trans-phosphorylate one
another at tyrosine residues in their cytosolic tails. These phosphorylated tyrosines can
then either bind directly to p85, the regulatory subunit of PI3K, or bind PI3K indirectly
through adaptor molecules and Ras. PI3K comprises catalytic (p110) and regulatory
(p85) subunits, both of which are targeted by mutation, usually in a mutually exclusive
pattern, in pHGG. pRB, RB protein.
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pHGGs[57-60]. Through genome-wide studies, PDGFRA, which encodes plateletderived growth factor receptor alpha (PDGFRα), was identified as the most commonly
targeted RTK in both DIPG and pediatric non-brainstem HGG (pNBS-HGG). Alterations
in the gene itself include amplification, mutation, or both[24, 50-52, 55, 56, 60-63].
Experimentally, overexpression of wild-type (WT) or mutant PDGFRα confers a growth
advantage to astrocytes, an effect that is diminished by the introduction of the adenosine
triphosphate-competitive inhibitors crenolanib or dasatinib. PDGFRα mutants drive
glioma formation in vivo[24, 25], with murine-derived HGGs recapitulating critical
features of the human disease such as histopathologic characteristics and expression
profiles[24]. In an effort to target PDGFR therapeutically, pediatric trials using dasatinib,
crenolanib, or imatinib have been launched[64-66]. Unfortunately, the benefit derived
from selective RTK inhibitors may be marginal at best. pHGGs show evidence of
intratumoral heterogeneity, with some cells co-amplifying multiple RTK genes or
discrete cell populations within the same tumor amplifying different genes, suggesting
that resistant populations are likely to be present even before treatment with targeted
agents[51, 61].
Both PDGFRA and EGFR are part of the RTK-Ras-PI3K signaling cascade,
which is altered in nearly 90% of aHGGs. Additionally, ~80%-90% of adult tumors show
evidence of RB and p53 pathway dysregulation[42-44, 67]. For this reason, many of the
first genetic pHGG studies focused on these same networks.
In adults, the most commonly targeted components of the RTK-Ras-PI3K axis
downstream of RTKs include activation of PI3K itself, or loss of function of phosphatase
and tensin homolog (PTEN), the main negative regulator of PI3K signaling, or NF1, a
negative regulator of Ras-mediated signaling[42-44]. Activation of PI3K signaling
caused by mutations of PIK3CA, encoding the catalytic p110α subunit of PI3K, or
PIK3R1, encoding the regulatory subunit of PI3K, is usually present in mutually
exclusive patterns, occurring in approximately 20% of aHGGs and in a similar frequency
of pHGG, including DIPG[8-11, 42, 62, 68-72]. The PTEN tumor suppressor is located
on chromosome 10q. It remains unclear whether all tumors with loss of chromosome 10q
are targeting PTEN loss of function when a WT PTEN allele is still retained. However,
there are examples in experimental systems where PTEN haploinsufficiency contributes
to tumorigenesis. Loss of heterozygosity (LOH) of chromosome 10q, with or without
concurrent PTEN mutation, is very frequent in adult glioblastoma, with 10q LOH in
approximately 80% and PTEN mutation in 25%-40%, whereas the frequency is
significantly lower in pHGGs, with 10q LOH in approximately 30% and PTEN mutation
in less than 5%-15%[8, 42, 50-53, 55, 56, 60-63, 69, 73-75].
RB pathway dysregulation is common in both pNBS-HGGs and DIPG. The
CDKN2A locus codes for 2 tumor suppressors, p16INK4a and ARF[45]. Notably,
homozygous deletion of CDKN2A/B appears to be almost exclusive to pNBS tumors and
largely absent in DIPGs[50-52, 55, 56, 60-63, 76]. In contrast, amplification of CDK4/6
or CCND1/2/3 is found in approximately 30% of DIPG[51, 55, 61]. Therapeutic
inhibition of this cyclin-CDK complex, using PD-0332991, a highly-selective non–
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adenosine triphosphate–competitive CDK4/6 inhibitor, significantly increased survival in
a murine model of DIPG, both as a single agent or following irradiation[77].
TP53 mutations occur in up to 35% of pNBS-HGGs (range: 18%-35%) and
appear to be more common in DIPGs (40%- 50% of cases)[8-11, 54, 62, 67, 69, 73-75,
78, 79].
From the aforementioned data, we can conclude that although the 3 main
signaling pathways affected in aHGG are also affected in pHGG, pediatric and adult
tumors differ regarding the most frequently mutated effectors.
Despite some common copy number imbalances such as 13q and 14q loss in
approximately one-third of patients with HGG regardless of age or location, aHGG and
pHGG also exhibit a unique constellation of gains and losses that distinguish one from
the other, and the same can be said for DIPGs and pNBS-HGGs[50-52, 55, 56, 60-63].
This suggests that unique combinations of genetic drivers underlie adult and pediatric
tumorigenesis, and among childhood HGG, DIPG and pNBS-HGG tumorigenesis.
Transcriptional analysis of tumors supports similar conclusions. Clustering of
gene expression signatures from aHGGs identifies 3-4 major gene expression subgroups,
with the most robust distinction between proneural and mesenchymal subgroups[32, 8082]. Unlike the WNT and sonic hedgehog subgroups of medulloblastoma (another type of
pediatric brain tumor)[83], the mutations associated with particular HGG subgroups are
much less consistent. These same subgroups were identified in pHGGs by unsupervised
comparisons, showing a clear relationship in the gene expression signatures of gliomas
among different age groups and locations. However, supervised comparisons revealed
expression signatures that distinguished adult from pediatric tumors, and within
childhood glioma, DIPGs from pNBS-HGGs[51, 52, 55, 61, 84, 85].
Because biopsy on patients with DIPG is not routinely performed in the United
States, most research material is acquired at autopsy from irradiated patients. The vast
majority of these samples are designated grade IV[86]. In contrast, clinicians in France
regularly perform pretreatment biopsies, and although most samples were HGGs, some
were classified as low grade[87], raising the possibility that there may be a low-grade to
high-grade malignant transformation in the genesis of DIPG. Importantly, there is a high
degree of similarity in the copy number imbalances and expression signatures from
DIPGs collected as biopsy samples before treatment and those collected at autopsy,
which were treated by radiation in most cases, with or without chemotherapy[51, 61].
Furthermore, expression signatures of pediatric brainstem LGGs are much more closely
related to non-brainstem LGG and not to DIPGs, emphasizing a different etiology
underlying genesis of LGG and HGG arising in the brainstem[51].
This body of work established the concept that oncogenic events driving pediatric
HGG were different from those arising in adults. This appreciation, however, was not
fully cemented until early 2012, with the discovery of recurrent histone mutations in
pHGG (Figure 1-2). As the first reports of histone mutations in human cancer, these
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Figure 1-2. Hot-spot histone mutations occur in nearly 80% of DIPGs and ~35%
of NBS-HGGs.
(A) The basic unit of chromatin is the nucleosome, in which the DNA is wrapped around
a histone octamer consisting of 2 copies of H2A, H2B, H3, and H4. The N-terminal tails
of histones undergo post-translational modifications (PTMs), represented by yellow and
blue circles, which in turn alter chromatin accessibility and recruitment of effector
proteins, together influencing transcriptional permissiveness. This is accomplished
because PTMs can (1) themselves alter the strength of DNA-histone interactions and (2)
facilitate recruitment of chromatin remodeling complexes or histone PTM-binding
effector proteins. (B) p.K27M substitutions occur in histone H3.1 and H3.3; p.G34R/V
substitutions occur in H3.3. Histone H3.1/3.3 p.K27M exerts a dominant effect,
preventing the accumulation of H3K27me2/3 on the wild-type histone H3 expressed in
the same cell. p.G34R/V mutations do not exert the same effect on H3K27me3, but
p.K27M and p.G34R/V histone mutations are associated with distinct genome-wide DNA
methylation and gene expression tumor signatures. (C) Table summarizing the functional
consequences of histone mutations.
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publications implicated novel mechanisms in pHGG tumor biology that are not found to
play a significant role in the adult disease.
Whole-genome sequencing of 7 DIPGs and matched germline DNA, as part of the
St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome
Project, identified somatic mutations in H3F3A leading to a p.K27M substitution in
histone H3.3 in 4 of 7 cases. A fifth case contained an analogous mutation in HIST1H3B
yielding a p. K27M alteration in histone H3.1. Subsequent targeted sequencing of all 15
genes encoding histone H3 in a larger cohort of pHGG found p.K27M somatic mutations
in 78% of DIPGs: 60% were mutations in H3F3A and 18% in HIST1H3B[88]. Similar
frequency of histone H3 mutation was found in an independent cohort; however, the
proportion of H3F3A and HIST1H3B mutations varied between the groups, likely owing
to patient age, with HIST1H3B mutations arising in younger children[88, 89]. In pNBSHGG, H3F3A and HIST1H3B p.K27M substitutions were found in 19% and 3% of cases,
respectively. Additionally, 14% of pNBS-HGGs harbored somatic mutations in H3F3A
leading to p.G34R substitution, whereas no such alteration was identified in any DIPG.
Most of the DIPG samples evaluated were collected at autopsy. However, of 8 DIPG
samples collected from patients who had not received adjuvant therapy, 7 contained
p.K27M substitutions. Hence, histone H3 alterations were not necessarily secondary to
therapy[88].
Collaborating groups in Canada and Germany performed whole-exome
sequencing of 48 pNBS-HGGs and identified p.K27M, p.G34R, and p.G34V alterations
in 19%, 10%, and 2% of cases, respectively, with all changes affecting H3F3A encoding
the histone H3.3 variant. Additional targeted sequencing of the H3F3A locus in more
than 700 samples of gliomas of various grades from patients of different ages revealed
these mutations to be exclusive to high-grade tumors and significantly enriched in
pediatric cases. Of the 11 adult cases harboring H3F3A mutation, all were missense
substitutions of G34, and the majority were identified in young adults aged 20-30 years.
The specific histone mutation was associated with anatomical location. p.K27M
mutations occurred in tumors involving midline structures (such as the brainstem,
cerebellum, and thalamus), whereas p.G34R/V mutations occurred in non-midline
supratentorial lesions (Figure 1-3) [8, 69].
Nucleosomes are the basic unit of chromatin, in which DNA is wrapped around a
nucleosome core composed of a histone octamer with 2 copies each of histones H2A,
H2B, H3, and H4. H3F3A and HIST1H3B code for the 2 histone H3 variant isoforms
H3.3 and H3.1, respectively. There are 3 isoforms of histone H3. Histone H3.1 and H3.2
are encoded by 10 and 3 separate genes, respectively, and are synthesized during S phase
of the cell cycle to package newly replicated DNA. Histone H3.3 is synthesized
throughout the cell cycle and selectively incorporated into promoter regions of active
genes, and through interactions with ATRX (alpha thalassemia/mental retardation
syndrome X-linked) and DAXX (death domain-associated protein 6), into pericentromeric heterochromatin and sub-telomeric regions[90]. Notably, recurrent ATRX
loss-of-function mutations were found in approximately one-quarter of pHGG, which
were also associated with alternative lengthening of telomeres. All tumors with H3F3A
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Figure 1-3. Histone mutations are strongly associated with anatomical location.
Midsagittal (A) and coronal (B) magnetic resonance images demonstrate that p.K27M
mutations occur predominantly in tumors involving midline structures (the brainstem,
cerebellum, and thalamus), whereas p.G34R/V mutations mainly occur in tumors arising
in the cerebral hemispheres.
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p.G34R/V mutation carried concomitant ATRX mutations, suggesting synergy between
the 2 mutations[69].
All identified histone mutations occur in the N-terminal tails of histones,
unstructured regions that undergo extensive post-translational modification. These
modifications in turn facilitate recruitment of effector proteins that regulate
transcriptionally active or silent chromatin states[91].
All histone H3 mutations in pHGG were heterozygous, and in any individual
tumor, only 1 of 15 genes encoding histone H3 was mutated. This pattern clearly
indicates a dominant gain-of-function effect.
Advances in microarrays and next-generation sequencing technologies have
provided unprecedented insight into pHGG biology. These studies, both large and small
scale, genome-wide and targeted, have given today's researchers and clinicians a better
understanding of pHGG than ever before.”
Closing Introductory Remarks
One hurdle shared by all researchers in studying pHGG is the relative lack of
available biomaterial, with only several hundred new cases diagnosed in the United
States each year[12]. This dissertation begins with the analysis of a cohort of 127 tumors
by next-generation sequencing. The next chapter is the publication that resulted from
those efforts with the subsequent chapter being an extension of one of the main findings
from that report.
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CHAPTER 2. THE GENOMIC LANDSCAPE OF DIFFUSE INTRINSIC
PONTINE GLIOMA AND PEDIATRIC NON-BRAINSTEM HIGH-GRADE
GLIOMA*
The second chapter of this dissertation will be the publication that resulted from
our analysis of 127 pHGGs, both DIPGs and NBS-HGGs[8]. Quoted text is taken from
the manuscript. This study was a collaborative effort between our laboratory and Dr.
Jinghui Zhang’s group in the Department of Computational Biology. I shared first
authorship with Dr. Gang Wu who spearheaded the bioinformatic analysis of sequence
data. My contribution was the functional study of the two primary genetic alterations
described below.
“Although childhood and adult HGGs share related histopathological
characteristics, adult HGGs arise predominantly in the cerebral cortex, whereas childhood
HGGs more frequently involve a broader spectrum of locations. There are also
substantial differences in the molecular features of pediatric and adult HGGs[43, 44, 5052, 55, 56, 61, 63, 69, 84, 92]. Histone H3 gene (H3F3A andHIST1H3B) mutations
encoding p.Lys27Met are frequent in DIPGs, which arise in the brainstem almost
exclusively in children, and in pediatric HGGs in midline structures such as the thalamus
and cerebellum, whereas histone H3 gene mutations encoding p.Gly34Arg or p.Gly34Val
occur in pediatric HGGs of the cerebral cortex[69, 88, 89, 93]. In contrast, histone H3
gene mutations are extremely rare in adult HGGs[69]. HGGs arising in infants younger
than 3 years of age have a better prognosis and a lower frequency of TP53 mutations,
suggesting that there may be age-dependent subgroups of HGG, even within the pediatric
population[94]. Thus, the selective pressures driving gliomagenesis in children vary with
age and anatomical site.
To more comprehensively understand the pathways driving childhood glioma, we
analyzed the genomic landscape of HGGs from 118 pediatric cases (127 tumors, 108
matched to germline DNA) consisting of 57 DIPGs and 70 NBS-HGGs by wholegenome (n = 42), whole-exome (n = 80) and transcriptome (n = 75) sequencing. A total
of 39,590 sequence mutations, including single-nucleotide variations (SNVs) and small
insertions or deletions (indels), and 2,039 structural variations were found by wholegenome sequencing, and an additional 2,600 sequence mutations and 138 structural
variations were found by exome sequencing and transcriptome sequencing, respectively.
Overall, the cohort showed a median background mutation rate of 9 x 10−7 mutations per
base and a median of 22 structural variations per genome. All SNVs and structural
variations found by whole-genome sequencing were verified experimentally by
independent sequencing methods.
____________________________
*
Reprinted with permission. Wu, G., Diaz, A.K., et al., The genomic landscape of diffuse
intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet,
2014. 46(5): p. 444-50.
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Among recurrent mutations in pediatric HGG, the most frequently mutated gene
not previously identified in cancer was ACVR1 (also known as ALK2) encoding a bone
morphogenetic protein (BMP) type I receptor (Figures 2-1 and 2-2). Clonal
missense ACVR1 mutations were found exclusively in DIPGs (32%) and were
significantly associated with younger age, longer survival time and the presence
of HIST1H3B mutation encoding p.Lys27Met (P < 0.0000001) or
with PIK3CA or PIK3R1 mutations (P < 0.005) (Figures 2-1 and 2-2). Four of these
somatic ACVR1 mutations were the same as germline mutations previously identified in
the autosomal dominant syndrome fibrodysplasia ossificans progressiva (FOP), in which
aberrant cellular differentiation drives progressive heterotopic ossifications[95, 96]. All
residues affected by mutation in DIPGs clustered around either the inhibitory glycineserine-rich (GS) domain or the ATP-binding pocket of the kinase domain and would be
expected to shift the kinase to an active conformation (Figure 2-2)[97]. Indeed,
mutations affecting these residues induced a weak gain of function[97, 98]. A previous
study showed that the ACVR1 mutation encoding p.Arg206His caused a ventralized
phenotype in zebrafish embryos, an indicator of BMP pathway activation[99]. We tested
all of the ACVR1 mutations found in DIPG using this assay. Zebrafish embryos injected
with wild-type human ACVR1 mRNA displayed a mild dorsalized phenotype consistent
with BMP pathway inhibition, whereas injection with mRNA for all six ACVR1 mutants
resulted in varying degrees of ventralization, with partial to complete loss of head and
dorsal structures (Figure 2-2b, c). A moderate dose of LDN-193189, a highly selective
antagonist of the BMP pathway[99, 100], partially reversed the ventralization effects
induced by ACVR1 mutants, as demonstrated by the rescue of dorsal head structures for
the Arg258Gly, Gly328Glu, Gly328Trp and Arg206His mutants and the reduced severity
of ventralization for the Gly356Asp and Gly328Val mutants (Figure 2-2c). Expression of
ACVR1 mutants in mouse primary astrocyte cultures caused increased levels of
phosphorylated SMAD1 and SMAD5 (SMAD1/5), a downstream indication of active
BMP signaling, with varying magnitude (Figure 2-2d). LDN-193189 also effectively
blocked signaling to phosphorylated SMAD1/5 downstream of mutant ACVR1 in
primary astrocytes.
Recurrent and clonal activating mutation of ACVR1 in 32% of DIPGs provides
strong evidence that ACVR1 is an oncogenic driver in this disease. However,
germline ACVR1 mutation in the genetic syndrome FOP is not associated with cancer
predisposition, indicating that ACVR1 mutation likely provides a selective advantage in
the presence of other critical mutations rather than driving tumor initiation. Consistent
with this hypothesis, all six of the DIPG-associated ACVR1 mutants failed to
render Tp53-null mouse astrocytes tumorigenic when implanted into the brain (data not
shown). BMP signaling is associated with contrasting effects dependent on context,
driving astrocytic differentiation or the proliferation of early hindbrain progenitors[101].
In tumors, BMP signaling induced the differentiation of medulloblastoma[102] but drove
either a differentiation or proliferation response in glioblastoma stem cells, related in part
to the epigenetic state of the cell[103, 104]. These context-dependent consequences likely
drive the exclusive association between ACVR1 mutation and DIPG.
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Figure 2-1. Recurrent genetic alterations in pediatric HGG.
Genetic alterations detected in 19 genes, including ACVR1 and the genes most recurrently
mutated in the pathways indicated on the left, are displayed. A diagonal white line
indicates loss of the wild-type allele or a male case for ATRX, which is X linked. H3F3A
(H3.3) and HIST1H3B (H3.1) mutations are grouped together in the category histone H3.
Structural variants involving NTRK1, NTRK2 or NTRK3 and copy number variants
(CNVs) of components of the CCND1, CCND2, CCND3, CDK4 or CDK6 G1 checkpoint
complex are grouped together. Tumor subgroup (DIPG or NBS-HGG), location of NBSHGG (midline versus cerebral hemisphere) and World Health Organization (WHO)
tumor grade are indicated. White boxes for location or tumor grade indicate information
not available. Mutations for 112 HGGs are shown. Four hypermutator samples and 11
samples for which only RNA-seq data were available were excluded from this summary.
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Figure 2-2. ACVR1 mutations in DIPG activate BMP signaling.
(A) Missense ACVR1 substitutions in DIPG were clustered in the GS or kinase domains.
Each red circle indicates a DIPG carrying the specified alteration, and an asterisk
indicates alterations previously found as germline mutations in individuals with FOP. The
extracellular domain (EC) and transmembrane domain (TM) were not affected by
mutations. (B) Human ACVR1 mutants ventralize zebrafish embryos. The graph shows
the percentage of embryos exhibiting a dorsalized or ventralized phenotype. Embryos
injected with wild-type ACVR1 mRNA (WT) showed a dorsalized phenotype, whereas
embryos injected with mutant ACVR1 mRNA showed a ventralized phenotype
(increasing severity from left to right). The Arg258Gly mutant had the least severe effect,
resulting only in the V3–V4 ventralized phenotype, whereas the Gly328Val mutant had
the most severe effect, with 90% of embryos showing the V5 ventralized phenotype. The
number of embryos examined is shown on top. (C) Representative phenotype images of
zebrafish embryos injected with the indicated ACVR1 mRNA. Untreated embryos
expressing the Arg258Gly, Gly328Glu, Gly328Trp and Arg206His mutants have few to
no dorsal structures, and embryos expressing the Gly356Asp and Gly328Val mutants are
more severely affected. Treatment with LDN- 193189 reversed the ventralization effects
of mutant ACVR1, as demonstrated by the partial rescue of dorsal structures (e.g., the
head) in embryos expressing the Arg258Gly (100%, n = 20), Gly328Asp (83%, n = 23),
Gly328Trp (100%, n = 20) and Arg206His (100%, n = 27) mutants and the reduced
severity of ventralization showing a decrease in the proportion of embryos with the V5
phenotype without the formation of dorsal structures for embryos expressing the
Gly356Asp (89%, n = 27) and Gly328Val (49%, n = 24) mutants. Scale bar, 200 µm. (D)
ACVR1 mutations drive increased levels of phosphorylated SMAD1/5 (pSMAD1/5) in
primary astrocyte cultures. Protein blots are shown for lysates of primary astrocytes
isolated from the brainstem of neonatal mice with conditional knockout of Tp53
transduced with retroviruses expressing Flag-tagged wild-type ACVR1 or the indicated
mutants and serum starved for 2 h. Quantification of the ratio of phosphorylated SMAD
to total SMAD normalized to the empty vector control is shown below.
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Principal-component analysis using the 1,000 most variable probe sets showed
that HGG samples clustered by tumor location with no segregation of DIPGs
by ACVR1 mutation status. Genes involved in the regulation of immune system processes
showed significantly different expression in DIPGs with and without ACVR1 mutation
(Fisher's exact test, P = 0.0002, false discovery rate (FDR) = 0.26%).
Structural variants generating fusion genes were common and were identified in
47% of pediatric HGGs, in equal proportions of DIPGs and NBS-HGGs, from
transcriptome and whole-genome sequencing data. Gene fusions involving the kinase
domain of each of the three neurotrophin receptor (NTRK) genes and five different Nterminal fusion partners were identified in 4% of DIPGs and 10% of NBS-HGGs.
Notably, 40% (4/10) of NBS-HGGs in children younger than 3 years old contained
an NTRK fusion gene (Figures 2-1 and 2-3). The NTRK receptors transduce a wide range
of developmental signals in the nervous system, including the induction of neurite
outgrowth, differentiation and neuronal survival or death[105, 106]. NTRK fusion genes
have recently been identified at low frequency in low-grade pediatric astrocytomas as
well as in adult glioblastomas[107-109]. Two of the five NTRK fusions found in our
cohort, TPM3-NTRK1 and ETV6-NTRK3, were previously identified in other cancer types
and shown to be oncogenic[110-114].
To test the ability of NTRK fusion genes to drive glioma formation, we
implanted Tp53-null primary mouse astrocytes transduced with retrovirus expressing
Flag-tagged human TPM3-NTRK1 or BTBD1-NTRK3 into mouse brain. Both NTRK
fusions induced high-grade astrocytomas with very short latency and complete
penetrance (Figure 2-3b). The resulting tumors showed elevated levels of
phosphorylated AKT and p42/44 mitogen-activated protein kinase (MAPK), downstream
indicators of phosphoinositide 3-kinase (PI3K) and MAPK pathway activation.
Although NTRK-activating fusions were specifically found at high frequency in
tumors from infants, activation of receptor tyrosine kinase (RTK)-RAS-PI3K signaling
through other mutations was frequent across the entire cohort, occurring in 69% of
DIPGs and 67% of NBS-HGGs (Figure 2-1). In contrast to previous reports detecting
EGFRvIII expression in pediatric HGG[58, 59], we only detected EGFRvIII expression
in 1 of the 85 tumors analyzed by whole-genome sequencing or RNA sequencing (RNAseq).
In addition to recurrent histone H3 gene, ATRX and SETD2 mutations reported
previously[69, 88, 89, 93, 115], we also detected frequent mutations of other histone
writers and erasers and of chromatin-remodeling genes (Figure 2-4). Interestingly,
mutations affecting histone H3 writers were significantly more frequent in NBS-HGGs
(P = 0.007), whereas frequencies of mutations affecting histone erasers were not
significantly different in DIPGs and NBS-HGGs (P = 0.3). Although
only ATRX mutations were highly recurrent, collectively, this group of genes involved in
epigenetic regulation was targeted by mutation in 22% of DIPGs and 48% of NBSHGGs, excluding histone H3 gene mutations (Figure 2-4). These mutations were often
concurrent with missense mutations in histone H3 genes. Indeed, including histone H3
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Figure 2-3. Three structural variants generate oncogenic chimeric NTRK fusion
proteins.
(A) All fusions included the C-terminal kinase domain from NTRK1, NTRK2 or NTRK3
(blue). N-terminal fusion partners include the tropomyosin domain (yellow) of TPM3, an
actin-binding protein fused to NTRK1, and the BTB/POZ dimerization domain (gray)
and the Kelch domain (orange) from the topoisomerase I–interacting protein BTBD1 or
the pointed protein-protein interaction domain (purple) of the ETS transcription factor
ETV6 fused to NTRK3. The N terminus of the actin-binding protein vinculin (light blue;
VCL) was fused to NTRK2, and the N terminus of the ATP/ GTP-binding protein
AGBL4 (green) was fused to NTRK2. The functional carboxypeptidase domain of
AGBL4 is not present in the fusion protein. For each fusion protein, the dashed red line
shows the fusion point, with the amino acid positions of the N-terminal and C-terminal
fusion partners at the breakpoint indicated. The number of amino acids in each full-length
fusion protein is shown at the lower right of each fusion. (B) NTRK fusion proteins
induce high-grade astrocytomas. Tp53-null mouse primary astrocytes isolated from
neonatal cortex or brainstem were transduced with virus expressing Flag-tagged TPM3NTRK1 (top) or BTBD1-NTRK3 (bottom) and implanted into mouse brain.
Representative hematoxylin and eosin staining (of seven independent mice per construct)
shows pleomorphic tumor cells, many with features of astrocytic differentiation and high
mitotic activity. Tumors induced by BTBD1-NTRK3 showed the frequent presence of
giant cells reminiscent of giant cell glioblastoma. Immunohistochemical analysis showed
expression of Flag-tagged NTRK fusion proteins and elevated levels of phosphorylated
AKT (pAKT) and 44/p42 MAPK (p-44/p42 MAPK) in tumor relative to surrounding
normal tissue. Scale bar, 50 µm.
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Figure 2-4. Pediatric HGG alterations in histone modifiers or chromatin
regulators.
Alterations identified in NBS-HGG or DIPG are shown. Genetic alterations were
identified in proteins that attach (writers; above) or remove (erasers; below) posttranslational modifications of lysine residues (Lys4, Lys9, Lys18, Lys27, Lys36) in the
tail of histone H3, as well as proteins involved in modifications of other histones or
chromatin remodelers. Notably, there were no alterations in writers or erasers of Lys27,
which is directly mutated at high frequency in DIPG and, to a lesser degree, in NBSHGG. Ub, ubiquitination; ac, acetylation; ph, phosphorylation; H2, histone H2; H4,
histone H4.
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gene mutations, 91% of DIPGs, 70% of midline NBS-HGGs and 48% of hemispheric
NBS-HGGs contained mutations in histone genes and/or this subgroup of epigenetic
regulators. p.Lys27Met histone H3.3 or H3.1 alteration results in a dominant loss of trimethylation at lysine 27 of histone H3 (H3K27me3) in the entire cellular pool of histone
H3 proteins[116-119]. Mutations that modulate H3K27me3 levels by targeting
components of the Polycomb-repressive complex 2 (PRC2) that methylates H3K27 or the
H3K27 demethylases KDM6A and KDM6B are found in other tumor types[120-125].
However, there were no such mutations across the entire HGG cohort, including in
DIPGs with wild-type histone H3 genes, supporting the unique selective advantage of
p.Lys27Met alteration in pediatric HGG (Figure 2-4). Mutations in transcriptional
regulators that affect the epigenetic landscape were also found, including focal
amplifications of MYC and MYCN, which encode transcription factors that act to amplify
the levels of expressed genes across the genome[126, 127], and truncating mutations in
the transcriptional corepressor genes BCOR andBCORL1 (Figure 2-1).
There was an enormous range in the complexity of the somatic mutations driving
pediatric HGG. The ten NBS-HGGs in children under 3 years old showed significantly
lower mutation rates than the rest of the cohort (P < 0.0001), suggesting that only a small
number of driver mutations is required in tumors from this age group (Figures 2-5 and
2-6). ETV6-NTRK3 fusion was identified as one of only two non-silent alterations in
SJHGG082, a glioblastoma from a 1-month-old subject. Notably, NTRK fusion genes,
including two of the fusions found here, have been identified in multiple tumor types,
including those from very young children such as congenital fibrosarcoma, as well as in
papillary thyroid cancer, an adult disease[108, 110, 112-114]. The high frequency
of NTRK fusion genes in NBS-HGGs from children younger than 3 years of age, the
paucity of additional mutations in these tumors and the rapid tumor onset in our
experimental glioma model strongly suggest that these fusion genes are potent oncogenic
drivers in early postnatal brain tumor development.
Four tumors, 3 with matched normal DNA, were scored as hypermutators, with an
extremely high background mutation rate, including more than 800,000 somatic
mutations in SJHGG111 in which biallelic germline PMS2 mutations were identified
(Figure 2-6). Subject SJHGG003 carried a heterozygous germline PMS2 mutation and
developed a grade IV hemispheric malignant glioneuronal tumor (MGNT) and a separate
DIPG. Although both tumors independently acquired different somatic inactivating
mutations in the remaining PMS2 allele, the basal mutation rate in the first tumor arising
in this case, the MGNT (SJHGG003_D), was nearly 100-fold higher than in the DIPG
that arose 2 years later (SJHGG003_A), demonstrating the potential range in the tumor
mutation burden associated with inherited mutation in DNA mismatch repair genes
(Figures 2-5 and 2-6). Hypermutator tumors were excluded from the evaluation of
mutation frequency. Seven cases carried germline mutations in known cancer
predisposition genes, including TP53, PMS2, MSH6 and NF1.
Thirteen tumors (31%) analyzed by whole-genome sequencing had
chromothripsis[128], identified by complex rearrangements with multiple interconnecting
breakpoints corresponding to genomic segments with oscillating copy number states
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Figure 2-5. Circos plots showing the range of structural alterations in pediatric
HGG.
Circos plots display the genome by chromosome in a circular plot and depict structural
genetic variants, including DNA CNAs, intra- and interchromosomal translocations, and
non-sequence mutations. Orange, loss of heterozygosity (LOH); red, amplification; blue,
deletion. Sequence mutations in RefSeq genes: brown, missense SNV; red, indel; blue,
splice-site SNV. Genes at structural variation breakpoints: pink, gene involved in inframe fusions; blue, others. Subject SJHGG003 carried a germline PMS2 mutation and
developed two independent tumors, first a hemispheric malignant glioneuronal tumor
(SJHGG003_D) and, 2 years later, a DIPG (SJHGG003_A). The SNVs and indels for
these two tumors were too numerous to include. The hypermutator tumor with more than
800,000 somatic mutations had an extremely stable genome (SJHGG003_D), whereas the
second tumor with approximately 100-fold fewer SNVs carried typical genomic copy
number and structural abnormalities seen in other HGGs (SJHGG003_A), thus
demonstrating the broad range and complexity of mutations associated with germline
PMS2 mutation. SJHGG016_D is an infant NBS-HGG with a TPM3-NTRK1 fusion and a
very stable genome. SJHGG027_D is an NBS-HGG from a case with A-T, showing a
relatively stable genome. This tumor sample was collected before radiotherapy.
SJHGG004_D is a DIPG with chromothripsis driving BTBD1-NTRK3 fusion.
SJHGG044_D is an NBS-HGG showing dramatic chromothripsis. For the examples of
chromothripsis, the names of the genes disrupted by structural variants were too
numerous to display.
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Figure 2-6. Outlier analysis of the tier1 mutation rate in all pediatric HGGs.
Least median squares was used to find the narrowest interval containing at least 50% of
the samples (shown in yellow) in terms of their tier1 mutation rate. An approximate 95%
prediction interval was determined by modeling this interval as the inter-quartile range of
a normal distribution (shown by the gray box). Only samples with matched germline
DNA were used for this analysis. The mutation rate is significantly lower in tumors from
children less than 3 years of age than in the others (p = 0.0005823, Wilcoxon rank-sum
test), with NBS-HGG tumors from children less than three shown in blue and DIPGs
from children less than 3 years of age shown in turquoise. Germline mutations are shown
in red, with specific mutated genes labeled. Hypermutator samples were associated with
germline PMS2 mutations and outlier mutation rates were also seen in samples with
germline MSH6 or PMS2 mutation. In contrast, TP53 germline mutations show a range of
mutation rates, including an outlier for low mutation rate. Germline ATM mutation was
associated with a lower mutation rate than the narrowest bulk. A tumor from a patient
with germline NF1 mutation fell within the narrowest bulk.
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(Figure 2-5). In our cohort, chromothripsis resulted in oncogenic rearrangement,
including BTBD1-NTRK3 fusion and rearrangement or amplification of
PDGFRA and EGFR. Nearly half of all samples showing chromothripsis were collected
before adjuvant therapy, indicating that the mechanism underlying their occurrence was,
at least in some cases, independent of DNA-damaging therapeutics. SJHGG027_D, an
NBS-HGG arising in a child with ataxia telangiectasia (A-T), had a relatively stable
genome, despite a compromised DNA damage checkpoint due to the absence of
functional ATM, ataxia telangiectasia mutated (Figures 2-5 and 2-6). Multiple subclones were identified in almost all HGG tumors. A founder clone or a descendant of a
founder clone in the diagnosis tumor could seed the development of relapsed or autopsy
tumor.
We identified TERT promoter mutations in only 2% of DIPGs and 3% of NBSHGGs, in strong contrast to the frequency of 86% identified in adult primary
glioblastomas[129].
The genomic landscape of pediatric HGGs also includes frequent mutations in
common cancer pathways, consistent with previous reports[50-52, 55, 56, 61, 63,
69]. TP53 mutations occurred in 42% of pediatric HGGs and were mutually exclusive
with truncating mutations in the TP53-induced phosphatase PPM1D, previously shown to
impair the TP53-dependent G1 cell cycle checkpoint (Figure 2-1)[130]. The G1
checkpoint regulators CCND1, CCND2, CCND3, CDK4 and CDK6 were predominantly
amplified in DIPGs, whereas CDKN2A homozygous deletion was restricted to NBSHGGs (Figure 2-1). Taken together, mutations affecting cell cycle regulation, including
the TP53 and RB pathways, were found in 59% of pediatric HGG (Figure 2-1).
This global view of the genetic landscape of pediatric HGG defines critical
pathways driving a devastating spectrum of childhood brain tumors and identifies highfrequency mutations in potential therapeutic targets - ACVR1 in DIPGs and NTRK fusions
in NBS-HGGs in infants.”
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CHAPTER 3. FUSIONS INVOLVING THE NEUROTROPHIN FAMILY OF
RECEPTOR TYROSINE KINASES IN GLIOMAGENESIS
Neurotrophin Signaling
As mentioned previously, NTRK gene fusions appear to be oncogenic drivers in
multiple glioma types, both in adult and pediatric HGGs as well as pLGGs[8, 107-109],
and the genetic landscape of these tumors can differ markedly. pLGGs resemble infant
NBS-HGGs in having quiet genomes whereas adult glioblastoma and non-infant pediatric
HGGs exhibit higher mutation burdens[8-11, 107-109]. Such differences also extend into
the prognosis of these gliomas, further emphasizing the heterogeneity among them. For
adult and non-infant HGGs, the two-year survival rate is <30%[36, 40]. By contrast,
nearly 90% of children with LGG are alive a decade after diagnosis[131]. Although
infants with NBS-HGG do fare better than non-infants, the clinical course of these
patients is not akin to those with LGG[132], thereby debunking the idea that perhaps
infant HGGs are diagnosed erroneously as high-grade or that they are merely low-grade
tumors with high-grade histology.
The history of neurotrophin research is rich, dating back to the mid-20th century
and includes the seminal work of Rita Levi-Montalcini and Stanley Cohen. In 1986, they
were both awarded the Nobel Prize in Physiology and Medicine for the isolation of nerve
growth factor (NGF)[133, 134]. In addition to NGF, the neurotrophin family of growth
factors includes three other members: brain-derived neurotrophic factor (BDNF),
neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4). Collectively, these ligands and their
cognate receptors (the Trk RTKs as well as the structurally unrelated p75NTR) are critical
in the development of the nervous system. The consequences of neurotrophin signaling
are diverse; mediating cell survival, differentiation, synaptic plasticity, and dendritic
arborization as well as other cellular responses[135].
Neurotrophins are synthesized in the endoplasmic reticulum (ER) as precursors
(proneurotrophins) with an N-terminal prodomain. Proteolytic cleavage of this domain
either in the Golgi or secretory vesicles or extracellularly yields the mature ligand[136].
Existing as homodimers, mature neurotrophins can bind two different classes of cell
surface receptors, the Trks or p75NTR. The former consists of three structurally related
members (TrkA, TrkB, TrkC), while p75NTR is part of the tumor necrosis factor receptor
(TNFR) superfamily. While both receptor types can bind mature ligand, p75NTR can
additionally associate with proneurotrophins[137].
A common feature of the four neurotrophin gene loci is the existence of multiple
5’ exons with the most 3’ exon containing the open reading frame for the
proneurotrophin. Alternative splicing to include or remove certain 5’ exons leads to
multiple mRNA transcripts, each with a distinct promoter. In fact, BDNF mRNA has
been shown to be regulated by eight different promoters. Further transcriptional control is
achieved by virtue of the fact that all but one neurotrophin gene, NGF, contain alternative
polyadenylation sequences. And yet an additional level of complexity is seen for BDNF;
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with a natural antisense transcript which can form a duplex with the coding strand,
leading to RNA degradation. Although the role of these various transcripts remains to be
seen, collectively they highlight the necessity of highly intricate gene expression for the
development and maintenance of a functional nervous system[138].
Mature neurotrophins bind to Trk receptors. Alternative splicing of the sequence
corresponding to the extracellular domains of all three NTRK genes alters the affinity
each receptor has to the various ligands. Trk-neurotrophin coupling mediates receptor
dimerization and subsequent trans-autophosphorylation of tyrosine residues. These
phospho-tyrosines in turn activate three pathways associated with neurotrophins: the
PI3K, MAPK, and phospholipase C gamma (PLCγ) networks (Figure 3-1). PI3K and
MAPK signaling is initiated via the same residue whereas PLCγ activation occurs
through a different phospho-tyrosine. PI3K can bind directly to phospho-tyrosine by its
p85 regulatory subunit or through an adaptor complex including Shc, Grb2, and Gab1.
The catalytic portion of PI3K, p110, then converts phosphatidylinositol 4,5-bisphosphate
(PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3), with the product serving as a
docking site for pleckstrin homology (PH) domain-containing proteins, such as AKT.
Full enzymatic activity of AKT is achieved through dual-phosphorylation at T308 and
S473. At the same phospho-tyrosine responsible for PI3K activity, MAPK pathway
signaling initiates with recruitment of Grb2 and SOS. A guanine nucleotide exchange
factor, SOS then activates Ras and subsequently leads to downstream MAPK activation
via phosphorylation of both threonine and tyrosine within a conserved TEY motif of the
kinase domain. Together, both MAPK and PI3K converge on transducing signals for cell
survival, proliferation, growth, and protein synthesis. A direct binding site for PLCγ on
Trk is generated when the most C-terminal tyrosine of the receptor is phosphorylated. Trk
phosphorylation of PLCγ-1 Y783 is both necessary and sufficient to induce enzyme
activity. The expression of a second PLCγ isozyme, PLCγ-2, is restricted to immune
cells. Both PLCγ and PI3K are similar in that they alter member lipid composition by
acting on the same substrate. PLCγ hydrolyzes PIP2 yielding the second messengers
inositol trisphosphate (IP3) and diacylglycerol (DAG). Whereas the former facilitates
Ca2+ release from the ER, DAG remains membrane-bound and promotes protein kinase C
(PKC) signaling. Neurotrophin-Trk complexes are then internalized by clathrin-mediated
endocytosis and can be recycled back to the membrane or degraded. Collectively, this
process is known as canonical Trk signaling. Research has also identified two noncanonical Trk pathways: 1) neurotrophin-independent activation and 2) signaling via
truncated isoforms lacking a kinase domain. However, the biological importance of these
remains to be seen[139].
An enigma of sorts early during its study, p75NTR is another type of neurotrophin
receptor. Much of the confusion was initially due to the ability of p75NTR to mediate both
apoptotic and survival signaling. It has since been shown that these outcomes are highly
context-dependent and rely on the receptor’s ability to bind both proneurotrophins as well
as mature ligand and also on its ability to form complexes either with Trk or with the
type-1 receptor sortilin. Structurally, the intracellular domain lacks enzymatic activity
and serves as a scaffold for adaptor recruitment[140].
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Figure 3-1. The NTRK signaling pathway.
(A) Dimers of four ligands (NGF, BDNF, NT-3, NT-4) bind with varying affinity to the
three NTRK receptors (TrkA, TrkB, TrkC). Upon neurotrophin binding, Trk receptors
trans-phosphorylate at specific tyrosine residues. Phosphorylation of a C-terminal
tyrosine leads to activation of PLCγ. When a more N-terminal tyrosine is phosphorylated,
it results in activation of both MAPK and PI3K. (B) PI3K activation can occur through
direct binding of p85, the regulatory subunit of PI3K, to Trk receptors. Alternatively, p85
can bind indirectly through its association with adaptor molecules and Ras. The catalytic
p110 component of PI3K alters membrane lipid composition by converting PIP2 to PIP3,
with the latter resulting in AKT activation. Ras can also initiate the MAPK signaling
cascade. Both pathways transduce signals critical for cell survival, proliferation, growth,
and protein synthesis. (C) Similarly to PI3K, PLCγ alters membrane composition by
acting on PIP2 to generate the second messengers IP3 and DAG. The former facilitates
Ca2+ release from the ER whereas the latter induces the activity of PKC.
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Discovery of the first Trk receptor occurred when a novel gene fusion was
identified in colorectal cancer. Genomic rearrangement combined the N-terminal
sequence of TPM3, a tropomyosin gene, with a C-terminal sequence corresponding to the
kinase domain of a previously unidentified RTK[141]. Named for its fusion partner,
tropomyosin receptor kinase A, or TrkA as it would later be known, was the founding
member of a family comprising two other such molecules. That initial report was
published in 1986. Since then, additional NTRK fusion genes have been described across
multitude cancer types (in both adult and childhood malignancies within and outside the
CNS) with varying frequency (ranging from 0.2%-100%)[142]. And although those
numbers may change as larger cohorts are studied and detection methods become
increasingly sensitive, the fact remains that NTRK gene fusions drive tumorigenesis in
numerous cancer contexts.
We have recently analyzed 127 patient samples, both DIPGs and NBS-HGGs,
through whole-genome sequencing, whole-exome sequencing, and transcriptome
sequencing. Our efforts revealed that 40% of infant NBS-HGGs contain NTRK fusion
genes, and these were found in 7% of pHGGs overall. When ranked by tier 1 mutation
rate, infant tumors clustered together as having significantly quieter cancer genomes when
compared to non-infants[8]. These findings, coupled with the observation that infants have
a better prognosis than older children, suggests that infant NBS tumors are a distinct
subgroup within pHGG[36, 132]. Although less frequent, NTRK fusion genes also occur
in pLGG (nearly 4%)[107, 108] and adult glioblastoma (1%)[109]. Genomically, infant
HGG resembles pLGG in exhibiting few mutations whereas adult glioblastomas appear
more somatically altered both in terms of copy number alterations and SNVs. Thus NTRK
gene fusions are gliomagenic drivers throughout various development settings; yet it
appears as if gliomas driven by the same oncogene can vary in tumor phenotype as a
function of contextual differences. I hypothesize that the molecular heterogeneity of
NTRK-driven gliomas stems from a dynamic vulnerability to oncogenic events
inherent to developmental context.
Methods
Implant studies
Tumorigenesis implant studies were done as previously described[23]. Briefly,
hGFAP-cre[143] and Trp53loxP/loxP[144] mice were crossed to drive homozygous Tp53
deletion. Primary astrocyte cultures were established from postnatal day 2 (P2) pups.
Murine stem cell virus (MSCV) retroviral vectors were used to introduce expression of
C-terminally FLAG-tagged NTRK fusions. The MSCV vector contained an IRESmCherry fluorescent reporter. Transduction efficiency was obtained by flow analysis to
determine the percentage of cells expressing mCherry. Transduced astrocytes were
subsequently implanted into the brain of athymic recipient mice.
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Mouse dissection
Animals requiring dissection were given 1mL Avertin (12.5mg/mL) IP. Mice
subsequently underwent thoracotomy and after puncture of the atria, were perfused with
PBS. Harvested brain tissue was subsequently placed in 4% PFA and whenever possible,
additional snap frozen material was collected. Tails were collected to confirm initial
genotyping results.
Mouse modeling
Mouse modeling was based on the Etv6-NTRK3 genetically engineered mouse
model previously generated for the study of breast cancer in the lab of Dr. Stuart Orkin
[114]. Briefly, the human NTRK3 cDNA sequence encoding the kinase domain was
inserted into exon 6 of one of the murine Etv6 alleles. A lox-stop-lox cassette was placed
immediately upstream from the cDNA sequence yielding a conditional knock-in allele.
Tp53loxP/loxP mice[144] were also used to generate heterozygous and homozygous floxed
alleles. Cre-mediated recombination was achieved using the transgenic nestin-cre (NCre)
line, which utilizes enhancer and promoter elements of rat origin[145]. NCre has
widespread expression of recombinase in the CNS beginning midway through
embryogenesis (E10.5). We additionally utilized Rosa26-stop-EYFP mice as a reporter
for Cre activity. In this line, the sequence encoding enhanced yellow fluorescent protein
gene (EYFP) was inserted into the Rosa26 locus with an upstream lox-stop-lox
sequence[146]. Expression of YFP will therefore be limited to cells in which Cre is
active.
Immunohistochemistry/Immunofluorescence
Harvested brain tissue was placed in 4% PFA in 1x PBS for 24h. Samples were
then processed and embedded in paraffin. Sectioning of tissue was done at a thickness of
5 microns. Slides to be stained were deparaffinized and rehydrated. Slides were placed in
citric acid (pH = 6) and heated until boiling for antigen retrieval. Endogenous peroxidase
was quenched by placing slides in 0.6% H2O2 for 30 minutes. For blocking of nonspecific binding sites, slides were incubated in 10% goat serum in TBS-T (0.01% Tween20 in TBS) for 1h. Afterwards, blocking solution was removed and primary antibody was
diluted in 2% goat serum in TBS-T, with slides left to incubate overnight at 4°C. For the
second day of staining, slides were incubated with the species-appropriate biotinylated
secondary antibody in 2% goat serum in TBS-T for 1h at room temperature. Since
secondary antibodies were biotinylated, signal amplification occurred though avidinbiotin complexing for 30m at room temperature (Vector Laboratories, catalog number:
PK-6100). NovaRed (Vector Laboratories, catalog number: SK-4800) and DAB (Vector
Laboratories, catalog number: SK-4100) were the substrates utilized. Slides were then
counter-stained, dehydrated, and coverslipped. Antibodies used: anti-FLAG (SigmaAldrich, F1804), anti-pPLCγ1 T783 (Cell Signaling Technology, 14008), anti-pAKT
S473 (Cell Signaling Technology, 9271), anti-p-p42/44 MAPK Thr202/Tyr204 (Cell
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Signaling Technology, 4370), anti-Ki67 (Novocastra, NCL-Ki67p), anti-Olig2
(Millipore, MABN50), and anti-Sox2 (Millipore, AB5603).
Results
NTRK fusion genes were found in 40% of infant NBS-HGG and in 7% of our
overall pHGG cohort. Interestingly, one of the fusion genes, ETV6-NTRK3, has been
described in other pediatric neoplasms such as congenital fibrosarcoma and congenital
mesoblastic nephroma[147-149]. So to test the ability of ETV6-NTRK3 to drive glioma
formation in vivo, we conducted an implantation study. Cortical astrocytes were
harvested from hGFAP-cre;Tp53loxP/loxP P2 pups and primary cultures were established.
Astrocytes were transduced with either an empty vector MSCV construct or one coding
for ETV6-NTRK3, both with a mCherry fluorescent reporter. Transduction efficiency was
1.5%-2% for ETV6-NTRK3 based on flow analysis. 2x106 cells were implanted into the
cortex of CD-1 nude mice. Animals injected with astrocytes expressing ETV6-NTRK3
had a median survival of 36 days (Figure 3-2). The tumors from these mice were
formally diagnosed as HGG and show evidence of MAPK and PLCγ activity by IHC
analysis. Fusion protein expression was confirmed by IHC detection of a C-terminally
engineered FLAG tag (Figure 3-2).
In addition to our pHGG cohort, NTRK fusion genes have been found in pLGG
and adult glioblastoma[107-109]; meaning the same driver promotes tumor formation in
diverse contexts. This prompted us to examine how oncogenic potential changes as a
function of developmental setting. To this end, we utilized genetically engineered mouse
models. Subsequent experiments utilized three such models described in the “Methods”
section of this chapter: Etv6-NTRK3 (EN3) knock-in, Nestin-cre (NCre), and Tp53loxP/loxP
mice. We initially crossed heterozygous EN3 males to hemizygous NCre females to
generate offspring that were positive for both alleles. Brainstem and cortical primary
astrocyte cultures were established from P2 pups. A cell viability assay (XTT) was
performed which showed an increase in cells expressing the fusion gene compared to
controls (Figure 3-3). Expression of EN3 was confirmed by RT-PCR. Mice were bred to
include Rosa26-stop-EYFP so that Cre activity could be determined. Over 90% of cells
were YFP-positive by flow analysis.
In addition to mice with WT Tp53, we bred in Tp53 floxed alleles to generate
NCre;EN3;Tp53+/- and NCre;EN3;Tp53-/- progeny. Tumor development was
incompletely penetrant with WT Tp53, at least by gross examination. Five mice exhibited
neurological symptoms and had tumor development that was apparent during dissection.
Seven had to be euthanized due to unrelated health issues, such a paraphimosis or rectal
prolapse, but one of these had evidence of tumor upon histological review. Seven mice
were euthanized or died without neurological abnormality and did not have gross
evidence of disease. Analysis of NCre;EN3 mice remains ongoing and paraffinembedded tissue will need to be sectioned and evaluated microscopically. We were taken
aback at the rate of tumor development in NCre;EN3;Tp53-/- mice, with a median
survival of 18 days (Figure 3-4). The median survival of NCre;EN3;Tp53+/- mice was 58
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Figure 3-2. Astrocytes expressing ETV6-NTRK3 generate HGG when implanted
into recipient mice.
Tp53-null astrocytes were transduced with retrovirus encoding ETV6-NTRK3 with a Cterminal FLAG tag. Cells were subsequently implanted into the cortex of
immunocompromised mice. (A) Kaplan-Meier comparing mice injected with astrocytes
transduced with ETV6-NTRK3 or empty vector retrovirus. (B) ETV6-NTRK3 drives
HGG formation with activation of MAPK and PLCγ. 20x H&E and IHC sections using
antibodies targeting the indicated epitopes.
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Figure 3-3. Expression of EN3 confers a proliferative advantage in vitro.
XTT from brainstem and cortical primary astrocytes harvested from NCre and NCre;EN3
P2 pups. Findings consistent throughout all three replicates.
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Figure 3-4. Kaplan-Meier curve of five cohorts: NCre;EN3;Trp53-/- (red),
NCre;EN3;Trp53+/- (black), NCre;EN3 (purple), NCre;Trp53-/- (blue), and
NCre;Trp53+/- (green).
Five NCre;EN3 mice had neurological symptoms with evident tumor during dissection.
Seven NCre;EN3 animals were euthanized due to unrelated health issues; one tumor upon
histological review. Seven NCre;EN3 mice were euthanized or died without neurological
abnormality and did not have gross evidence of disease. Analysis of the NCre;EN3 cohort
remains ongoing.
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days. Tumors in NCre;EN3;Tp53-/- mice were diagnosed formally as HGG, exhibiting a
high-proliferative index (by Ki-67), infiltration of normal parenchyma, and satellitosis
(Figure 3-5). Tumors were analyzed by IHC to detect pAKT-S473 and p-p42/44 MAPK
Thr202/Tyr204, which is consistent with activation of PI3K and MAPK, respectively
(Figure 3-6).
Given the rapid onset, we were interested to see earlier stages of tumorigenesis in
NCre;EN3;Tp53-/- mice. We therefore examined the brains of P5 pups. Even by this time
point there was high-grade disease (Figure 3-7). To see if EN3 was driving
gliomagenesis in a tumor stem-cell-like population we performed immunofluorescence to
detect Olig2 and Sox2. P5 tumors were largely comprised of discrete cell populations of
either Olig2-positive or Sox2-positive cells. A very small minority of double-labeled cells
were found and these appeared near tumor edges (Figure 3-7). As previously mentioned,
NTRK signaling involves three pathways. In order to dissect the contribution each has on
tumor formation, we needed to establish tumor cell lines. Tumorspheres were generated
from three different NCre;EN3;Tp53-/- HGGs. To confirm that cultured cells were indeed
tumor (and not immortalized NSCs given their Tp53-null status), we implanted 250,000
cells into the cortex of immunodeficient mice. All injected mice developed HGG (Figure
3-8), indicating successful establishment of in vitro renewable models of the
NCre;EN3;Trp53-/- HGGs.
Discussion
To say ETV6-NTRK3 is a potent oncogenic driver would be an understatement.
Despite a transduction efficiency of 1.5%-2%, this fusion gene was able to generate
HGGs with a shorter latency than similar experiments with the majority of cells
expressing various PDGFRA mutants. But this was merely the beginning, as the mousehuman chimera of this same fusion protein was able to generate the first spontaneous
pediatric model of HGG. This is far and away the most significant aspect of this work.
For one, it provides a new platform for pre-clinical study. Our current approach to
analyzing potential therapeutic agents includes in vivo testing using an implantation
model. However, these experiments are in adult immunocompromised mice. The tumor
latency of NCre;EN3;Tp53-/- mice (median, 18 days) allows us to administer a compound
to not only see if the agent works, but to also ascertain the toxicology profile during a
physiologically relevant pediatric setting.
Our analysis continues. We collected snap frozen tissue and have since submitted
this for RNASeq in the hopes of identifying the downstream targets that render this
fusion gene so transforming. The EN3 knock-in model was initially developed for the
study of breast cancer. In that context, researchers discovered that the fusion protein’s
oncogenicity was through activation of the AP1 transcriptional complex. AP1 itself is a
dimeric complex comprised of members from the Jun, Fos, Maf, and ATF families. It
will be interesting to see if EN3-driven gliomagenesis acts similarly or engages another
downstream effector. Additionally, we will now look prenatally to uncover the initial
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Figure 3-5. NCre;EN3;Trp53-/- mice generate HGG.
(A) Sagittal H&E section of a P18 tumor-bearing mouse showing extent of disease
burden. (B) 10x H&E and Ki-67 sections demonstrate a high proliferative index. (C-F)
40x H&E. Native neurons are highlighted by arrows; mitotic figures are highlighted by
circles. (C) Moderate to severe cytologic pleomorphism, including some multinucleated
giant cells. (D) Infiltration of normal tissue by astrocytoma cells. (E) Mitotic figure. (F)
Tumor cells demonstrate some satellitosis around cortical neurons and a mitotic figure.
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Figure 3-6. Tumors from NCre;EN3;Trp53-/- mice show activation of PI3K and
MAPK.
20x H&E and IHC sections using antibodies targeting the indicated epitopes.
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Figure 3-7. NCre;EN3;Trp53-/- mice have high-grade disease by P5.
(A) Sagittal H&E section of a P5 mouse with evidence of HGG. (B) 20x H&E section
demonstrating sub-pial growth of infiltrating astrocytoma and involvement of the
Virchow-Robin spaces. (C-E) 40x H&E. Native neurons are highlighted by arrows;
mitotic figures are highlighted by circles. (C, E) Sections demonstrating infiltrating
astrocytoma with mitotic activity. (D) Section demonstrating infiltrating astrocytoma
with perivascular growth pattern. (F) 20x immunofluorescence of tumor and adjacent
normal with triple labeling of DAPI, Sox2, and Olig2. Image taken to show tumor
involvement of Virchow-Robin space. Tumor consists largely of two discrete
populations: singly labeled Olig2 or Sox2 positive cells. The few double positive cells
appear in tumor edges.
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Figure 3-8. Tumorspheres from NCre;EN3;Trp53-/- mice generate HGGs when
implantated into recipient mice.
Tumorsphere cell lines were established from a NCre;EN3;Trp53-/- tumor-bearing mouse
that was euthanized at P21. At passage 2, 250,000 cells were injected into the cortex of
immunocompromised mice. (A) All recipient mice were euthanized 26 days postinjection due to moribund status. (B) Sagittal H&E sections demonstrate that implantderived HGGs recapitulate features of the parental spontaneous tumor.
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stages of tumorigenesis; to see how expression of ETV6-NTRK3 affects native cell
populations during the beginning of the gliogenic window.
We are hopeful this model and these studies will yield insight into how these
tumors develop. Currently in the pHGG research community, phrases such as “unique
selective pressures” and “developmental context” form the backbone of our manuscript
introductions and discussions. They are essentially fancy descriptors of the black box that
is HGG formation in children. Perhaps now we can start to shed some light on this
process, giving our words a bit more meaning.
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CHAPTER 4.

DISCUSSION

ACVR1
ACVR1 mutations are somatic heterozygous missense alterations, with the
remaining WT allele intact. Even without considering any functional data, this pattern is
suggestive of gain-of-function; making mutant ACVR1 an oncogene.
The identification of ACVR1 mutations in DIPG was similar to the discovery of
histone mutations in that they both implicated novel biology in disease pathogenesis.
Although showing dysregulation in the 3 core pathways of HGG, prior genetic and
molecular studies had never found a role for BMP signaling.
BMPs belong to the transforming growth factor beta (TGFβ) superfamily along
with activins. They bind membrane receptors known as type II receptors. Two type II
receptors then bind two type I receptors, which ACVR1 is, forming a tetrameric complex.
When this occurs, type II receptors phosphorylate ACVR1 in a GS rich regulatory
domain. In the unstimulated state, this region forms a docking site for FKBP12, rendering
the kinase of the type I receptor inactive. Phosphorylation of this GS domain causes
FKBP12 to dissociate, allowing ACVR1 to phosphorylate its targets, the receptorregulated SMADs 1/5/8 (R-SMADs). A trimer is then formed consisting of two RSMADs and common-mediator SMAD4 (co-SMAD). This trimer subsequently
translocates to the nucleus and mediates expression of downstream targets including the
inhibitor of DNA-binding/differentiation (Id) family of transcription factors. Noncanonical BMP signaling is SMAD independent and leads to activation of p38
MAPK[150].
As previously mentioned, our group and others have shown that ACVR1
mutations render its kinase domain constitutively active. Recently, two publications have
uncovered an additional function: the ability of mutant ACVR1 to signal upon binding of
a traditional BMP antagonist, activin A[151, 152]. Normally, activin A transduces signals
along the TGFβ axis while simultaneously preventing BMP activation by binding
ACVR2A and ACVR2B, the type II receptors known to couple with ACVR1[150]. As a
result, when mutant ACVR1 is present, the pathway will be active whether or not ligand
is present and when inhibitor is present as well.
The p.K27 position of histone H3.1 and H3.3 can undergo mono-, di-, and trimethylation as well as acetylation, and these modifications are carried out by a number of
enzymes[90, 91, 120]. p.K27M mutations lead to a global loss of histone H3 K27 trimethylation, despite the mutant protein being a minority of the total cellular fraction of
histone H3[116-118]. After sequencing of our cohort, we were surprised to learn that the
evolutionary pressure in pHGG is specific for selecting p.K27M to reduce trimethylation, to the exclusion of possible alterations to the modification machinery
affecting that amino acid[8]. Similarly, the tumor dynamics within DIPG target the BMP
pathway solely through mutant ACVR1, conferring a selective advantage specific to the
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brainstem given these mutations are restricted to this area[8-11]. It is for these reasons, in
addition to frequency, that both these alterations are appealing therapeutic targets. These
tumors have selected very specific paths for achieving particular functional outcomes,
with no evidence of alternative mechanisms. That is not to say one would not emerge in
the face of targeted therapy. In fact, that is to be expected given how aggressive these
cancers are. For RTKs, resistant populations are already present even prior to any
proposed targeted agent; we see the same tumor targeting multiple RTKs either in the
same cell or in different subclones[51]. However, it seems that resistance would have to
be acquired in the case of ACVR1 and histone H3. Even if only transiently effective,
such treatments may add a month or two months to overall survival, which are
meaningful steps we need to take in order to reach our goal of a cure.
In individuals with FOP, mesenchymal stem cells aberrantly differentiate to
osteoblasts[95]. Knowing activin A mediates BMP signaling through mutant ACVR1
helps us to understand why heterotopic ossification is exacerbated by tissue injury.
Activin A is a known mediator of inflammation and works in antagonizing the BMP
pathway. However, mutant ACVR1’s capacity to phosphorylate R-SMADs upon activin
A binding transforms an environment that typically restricts the expansion of boneforming cells into one that promotes it. So is there an inflammatory component to HGGs?
Certainly; microglia can be seen in and around tumors and a hallmark of grade IV tumors
is necrosis. But these features are shared by all HGGs, regardless of age and location. It is
worth mentioning that we found BMP activation regardless of ACVR1 status, with no
appreciable difference in levels of phospho-SMAD 1/5 between mutant and WT
tumors[8]. Perhaps then all pHGGs rely on BMP signaling. More pronounced
inflammation may exist in certain tumors, initially suppressing pathway activity. But
once ACVR1 is mutated, the inflammatory milieu switches to promote BMP signaling.
This possibility is supported by the fact that an inflammatory expression signature
significantly associates with ACVR1 mutation[8].
Can restriction of ACVR1 mutation to the brainstem provide insight to a potential
cell of origin? BMP activation in NSCs promotes astrogliogenesis and prevents
oligodendrocyte differentiation[153]. Given no increase in cancer incidence in FOP
patients, we believe ACVR1 is playing a role in tumor progression rather than initiation.
Imagine then a scenario where a tumor in the brainstem is growing, causing local
inflammation. The microenvironment is now rich in cytokines and other molecules,
including activin A. A hypothetical cancer stem cell, a transformed NSC, acquires
an ACVR1 mutation that, rather than promoting terminal differentiation, leads to
unchecked proliferation of a tumor transit amplifying astrocytic population. Several cell
types have demonstrated gliomagenic potential, but perhaps the trajectory outlined above
occurs in a subset of DIPGs, given the enrichment of ACVR1 mutations in younger
patients. The pons itself is broken down into a ventral basis pontis and dorsal tegmentum,
and DIPGs are thought to arise from the former. So what is in this area of the pons?
Longitudinal and transverse fibers in addition to the pontine nuclei. There exists a
Nestin+ cell population in the human ventral pons that is most prevalent shortly after
birth. Interestingly, this cell type makes a resurgence in middle childhood, roughly
corresponding to the ages of highest incidence for DIPG[154].
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NTRK Gene Fusions and Infant NBS-HGG
To say we were taken aback at the oncogenic capacity of NTRK fusion genes
would be an understatement. Despite an abysmal transduction efficiency of less than 2%,
Tp53-null astrocytes transduced with an ETV6-NTRK3 retroviral construct managed to
generate HGGs within a few weeks after implantation. And in our spontaneous model,
when the mouse-human chimera of this same alteration is expressed with concomitant
Tp53 deletion in embryonic NSCs, it was able to establish true pediatric disease.
NTRK signaling involves three pathways: MAPK, PI3K, and PLCγ. Early
investigations looking at NTRK focused on the contribution of the first two and
understandably so, given their involvement in cancer. Site-directed mutagenesis of the
tyrosine responsible for PLCγ activation did not abolish the ability of fusion genes to
transform NIH3T3 cells[155], an immortalized line of mouse fibroblasts. However, that
is not to say the pathway is not contributing. We see evidence that it is active in our
systems, and part of the potency of NTRK fusion genes may very well stem from this
axis. PLCγ converts PIP2 to the second messengers IP3 and DAG. The former is
responsible for Ca2+ release from the ER while DAG remains membrane-bound and
activates PKC[139]. The list of downstream targets of the various PKC isozymes is
extensive. Yet those isozymes found to promote tumor formation have been linked to
activation of both PI3K and MAPK, in addition to upregulation of cyclin D leading to
pRb hyperphosphorylation[156]. Prolonged NTRK signaling leads to downregulation of
its associated receptors, including at the level of expression[139]. These fusion genes are
impervious to this type of regulation however as they are under the control of their Nterminal partner; which, in addition to the activation of three pathways, could contribute
to their oncogenic potential. We were intrigued to see that the NTRK fusion genes in our
cohort were not highly expressed as is the case with most other oncogenes[8]. Perhaps
this diminished susceptibility to transcriptional control circumvents the need for
increased expression to overcome potential inhibition.
Interestingly, the frequency of TP53 mutation is significantly less in infant NBSHGGs (10%) than it is in pHGG overall (55-70%)[7, 8]. Although we were able to
generate a few tumors without deletion of the gene, NTRK-driven gliomagenesis required
knockout of Tp53. The infant developmental context may require targeting of the
pathway by other means, such as upregulation of the p53 negative regulator MDM2 or
downregulation of the CDK inhibitor p21, itself a p53 effector. Given how barren these
tumors are mutationally, dysregulation of the aforementioned targets, or any others, may
occur at the epigenetic level rather than through genetic alteration. Then again, this
particular developmental setting may not require direct perturbation.
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.
And like pHGG, a small subset of these occur in very young children. Known as infant
ALL, these cancers typically arise within the first year of life. Similar to the enrichment
of NTRK fusion genes in infant NBS-HGG, infant ALL exhibits characteristic
rearrangements involving the mixed lineage leukemia (MLL) gene in a majority of cases
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(~80%)[157]. Another similarity between these two diseases is the paucity of somatic
mutations in their cancer genomes. But unlike the youngest pHGG patients who have a
better prognosis than older children, infants with ALL appear to have a particularly
aggressive disease and fare worse than non-infants. So what could account for this? MLL
is a methyltransferase responsible for histone post-translation modification, making it a
global transcriptional regulator. It would therefore be reasonable to suspect that
rearrangements leading to MLL fusions would involve its enzymatic SET domain, but
this is not the case. These gene fusions result in epigenetic deregulation and disrupt
transcription of target genes[157]. Any mutation that is selected for enhances
evolutionary fitness. And while the same could be said for those leading to epigenetic
dysregulation, there is a distinction between these alterations and others: widespread
epigenetic deregulation perturbs numerous genes rather than just one. In infant ALL we
see this whereas in infant NBS-HGG we do not, and this could potentially explain the
difference in prognosis between the two.
NTRK fusion genes drive HGG formation in a number of developmental settings:
in NBS tumors both in infants and older children, DIPG, and adult glioblastoma, which
arise predominantly in the cortex[8, 107-109]. A still unresolved issue in HGG biology is
the identification of a putative cell of origin. In the previous section of this discussion I
explored this subject as it pertains to DIPG. To summarize briefly, brainstem HGGs are
thought to arise from the ventral pons. A nestin-expressing precursor cell exists in this
area and is found to be at its highest numbers shortly after birth, slowly dwindling until
about 2 years of age. This population subsequently increases around the same time that
children typically are diagnosed with DIPG[154]. For adults, a legitimate case can be
made for NSCs, OPCs, and astrocytic progenitors as these are actively proliferating.
Various HGG models have been developed targeting genetic alterations in these cell
types[158]. Others might be tempted to include neurons as a potential cell of origin, but
arriving at such a conclusion would require a bit of mental gymnastics. Neurons are postmitotic, meaning that to be a HGG cell of origin, all necessary hits would have to occur
in the same cell or robustly induce proliferation of a post-mitotic neuron to increase the
likelihood of acquiring co-mutation of other critical genes. Possible? Yes, but unlikely.
The issue is a bit more complex and nuanced when we look at infant and noninfant HGGs outside the brainstem. In mice, gliogenesis begins by E15 and is largely
complete by the first month of postnatal life. The pediatric brain is therefore abundant
with mitotically active NSCs, OPCs, and astrocytic progenitors relative to the adult
brain[17]. Our experimental systems demonstrate that P2 astrocytes, through
implantation, and embryonically targeted NSCs have the capacity to generate HGGs.
However, we must keep in mind that although genetic alterations are targeted in a
specific cell type, it may be their more differentiated progeny that give rise to a
tumor[159]. Aside from age, there are two key differences between infants and noninfants with NBS-HGG that lead us to believe that they originate from different cell
types: 1) the difference in prognosis and 2) the difference in mutation burden. Infants fare
better than non-infants[132] and also have significantly quieter cancer genomes than
older children[8]. So what then could account for this? In their “Hallmarks of Cancer,”
Robert Weinberg and Douglas Hanahan detail the attributes a cell gains in the
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progression toward malignancy[160, 161]. To a certain extent, stem cells and cancer cells
resemble one another. Meaning that on the path leading to cancer, stem cells have a head
start so to speak and possess a number of these traits intrinsically. Maybe this ancestral
cell is what gives rise to infant tumors; its quiet genome a reflection of the minimal steps
needed to get disease. Maybe the cell of origin for older children falls more along the
differentiated side of the spectrum; with its mutation burden a reflection of the need to
acquire more requisite traits of transformation which it was originally lacking. This
remains an active area of investigation. In addition to using a constitutively active Cre,
we can use inducible forms, under the same and different promoters, to introduce Etv6NTRK3 in various cell types and ages to see: 1) how these alter a cell’s ability to be
transformed, 2) if the difference is due to a change in the transcriptional program, 3) if
the NTRK-associated pathways are equivalently contributing to that program, 4) if the
program is unique to NTRK fusion genes or shared by RTKs in general (comparing to a
different model in the lab using transgenic mutant PDGFRA), and 5) if the responsible
pathways can be targeted therapeutically. We are excited about this model for a number
of reasons. First and foremost, it provides us a unique platform to perform preclinical
testing. No other system yet described, be it implantation or spontaneous, generates HGG
in a pediatric timeframe. This minimal latency will also enable us to work backwards
from endpoint disease, similar to our P5 analysis, to see just how the fusion gene is
functioning and in which cell type, giving us an opportunity to see the multistep
tumorigenesis process in vivo. Tumorsphere cell lines can be established as well. By
treating these with inhibitors of the NTRK-associated pathways it will be possible to
determine if a particular axis is responsible for the fusion gene’s transcriptional program,
thereby revealing a potential therapeutic vulnerability.
A rather puzzling topic is that of NTRK fusion-driven infant NBS-HGG and
pLGG. Their histologies differ and so too do their prognoses, but they resemble one
another in that they are both minimally somatically altered. As previously mentioned, the
prognosis for infant NBS-HGG lies in-between that of older children with HGG and
pLGG. So what are the features of pLGGs harboring NTRK fusions? First, it should be
noted that we are talking about four cases discovered thus far[107, 108]. Actually, in our
cohort of pHGG, we had 10 infant tumors and four of those had NTRK gene fusions[8].
So between the two, we are talking about 8 cases total. But the four pLGGs that have
been identified are in children older than 3 years and with tumors in the cortex[107, 108].
Now for the hand-waving. One could see this age discrepancy and conclude that these
tumors arise from a different cell of origin or from the same cell but in a different time
point in development. But LGGs are, by definition, slow-growing. Let us entertain the
idea that both these tumors started from the same cell type. So how then do we account
for their differences? Perhaps those that progressed to high-grade acquired additional hits
but at the epigenetic level. Our spontaneous model indicates that NTRK-driven
tumorigenesis requires few cooperating events. And so we could literally be talking about
an alteration or two being the difference in this very specific instance.
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Closing Remarks
I was extremely fortunate to be a graduate student during a period of tremendous
growth in our understanding of the pHGG landscape. In the last 4 plus years the power of
unbiased interrogation via next-generation sequencing has given researchers the ability to
peer into the genetics of these tumors at an unprecedented level. The result? The
suspicions of yesterday are now the truths of today: pediatric and adult HGGs are related
but distinct. And when we take a closer look at children with HGG, we begin to
appreciate that even within this age group, there is a spectrum of disease. Our work and
the work of others identifies previously undescribed oncogenic drivers in different
subgroups of pHGG: histone p.K27M and ACVR1 mutations in DIPG, less frequent
p.K27M and FGFR1 mutations in thalamic tumors, H3F3A p.G34R/V alterations in
laterally-located cortical HGGs, and the enrichment of NTRK fusion genes in infant
NBS-HGG. This spatiotemporal distribution of genetic drivers underscores the
importance and the uniqueness of the selective pressures involved in pediatric
gliomagenesis.
This process, the doctoral training process, can be a whirlwind sometimes;
empowering you one day only to leave you exasperated the next. And this is a good
thing. Feeling that happiness and frustration is affirmation that you care about what you
do. As I transition back to medical school I do so with a sense of excitement; not only for
my own personal sake but also because I do so in a new era of pHGG study. The
community has done well in identifying the genetic events that drive these tumors. And
although we can take pride in those efforts, our satisfaction is short-lived. The imperative
now is to use this information to shape the next generation of clinical trials. So imagine
the position I find myself in: to have contributed in the research that leads to the trials I
may be involved with as a physician-scientist. I am humbly grateful, now and always.
Thank you.
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